This article is not stand-alone and must be read in conjunction with the SPS Q&A series “Questions about PGD signatories”.
The purpose of this article and the attached document is to provide an overview of the roles and responsibilities of the people who must sign the PGD as set out in legislation . See Section 8 Patient group directions (NICE guideline MPG2, 2017) – full guideline.
Roles and responsibilities of Patient Group Direction (PGD) signatories are listed as follows:
Section 1 :Role and responsibilities of a doctor (or dentist) signatory
Section 2 :Role and responsibilities of a pharmacist signatory
Section 3 :Role and responsibilities of the signatory who is a representative of the professional group expected to supply medicines under the PGD
Section 4 :Role and responsibilities of a Clinical governance lead involved in the organisational authorisation of the PGD
To help establish these roles and responsibilities, and to help provide further signposting to guidance, associated duties are listed against some relevant recommendations in Patient group directions (NICE guideline MPG2, 2017).
This article and associated document does not:
- Cover the responsibilities of lead authors of PGDs.
- Cover the roles and responsibilities of practitioners using PGDs. See Section 1.5 Patient group directions (NICE guideline MPG2, 2017).
- Cover the associated organisational governance responsibilities for PGDs. See Section 1.8 in Patient group directions (NICE guideline MPG2, 2017).
- Cover the knowledge, skills and expertise needed by people who are developing, updating, authorising and using PGDs. For competencies required to undertake all PGD roles and responsibilities including authorisation of PGDs: refer to the NICE PGD Competency Frameworks.
- Refer to differing local arrangements and scenarios for development and authorisation of PGDs. These must be separately considered to ensure the relevant formal arrangements with clearly defined roles and responsibilities of all involved.
To help ensure compliance with legislation and guidelines, organisations should use the NICE PGD Baseline Assessment Tool and refer to the recommendations in Patient group directions (NICE guideline MPG2, 2017).
Before and during the stages of developing and authorising PGDs, see To PGD or not to PGD and Quality PGDs – 7 steps for success – decision making tools to help organisations, potential authors and signatories consider whether PGDs are appropriate and to think about and follow necessary procedures.
Specialist Pharmacist (Patient Group Directions), Medicines Use and Safety Team